{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:09:38Z","timestamp":1784124578031,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canada Institutes of Health Research New Investigator Award"},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jsat.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:52:14Z","timestamp":1554375134000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods"],"prefix":"10.1016","volume":"101","author":[{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Palis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Guh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Brissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam H.","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8769-1785","authenticated-orcid":false,"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.03.012_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/add.14171","article-title":"Cost-effectiveness of hydromorphone for severe opioid use disorder: Findings from the SALOME randomized clinical trial","author":"Bansback","year":"2018","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jsat.2019.03.012_bb0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jsat.2019.03.012_bb0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12051","article-title":"Pharmacological maintenance treatments of opiate addiction","volume":"77","author":"Bell","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/j.jsat.2019.03.012_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","article-title":"Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction","volume":"203","author":"Byford","year":"2013","journal-title":"The British Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2019.03.012_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/dar.12088","article-title":"The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?","volume":"33","author":"Degenhardt","year":"2014","journal-title":"Drug and Alcohol Review"},{"issue":"4","key":"10.1016\/j.jsat.2019.03.012_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000369337","article-title":"Efficacy of heroin-assisted treatment in Belgium: A randomised controlled trial","volume":"21","author":"Demaret","year":"2015","journal-title":"European Addiction Research"},{"issue":"7410","key":"10.1016\/j.jsat.2019.03.012_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","article-title":"Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials","volume":"327","author":"van den Brink","year":"2003","journal-title":"BMJ"},{"issue":"7503","key":"10.1016\/j.jsat.2019.03.012_bb0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.330.7503.1297","article-title":"Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials","volume":"330","author":"Dijkgraaf","year":"2005","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jsat.2019.03.012_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0706743717711167","article-title":"The state of opioid agonist therapy in Canada 20 years after federal oversight","volume":"62","author":"Eibl","year":"2017","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.03.012_bb0050","article-title":"Heroin maintenance for chronic heroin-dependent individuals","volume":"12","author":"Ferri","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2019.03.012_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1503\/cmaj.131744","article-title":"Canada in breach of ethical standards for clinical trials","volume":"186","author":"Fletcher","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.jsat.2019.03.012_bb0060","article-title":"Nursing therapeutic relationship and its role on patients' daily attendance and street opioid use among patients receiving injectable opioid agonist treatment at Crosstown Clinic","author":"Foreman","year":"2018"},{"key":"10.1016\/j.jsat.2019.03.012_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","article-title":"Heroin-assisted treatment for opioid dependence: Randomised controlled trial","volume":"191","author":"Haasen","year":"2007","journal-title":"The British Journal of Psychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2019.03.012_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jsat.2006.04.007","article-title":"Controlled trial of prescribed heroin in the treatment of opioid addiction","volume":"31","author":"March","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2019.03.012_bb0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: A randomized double- blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.03.012_bb0080","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.03.012_bb0085","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1016\/j.jsat.2019.03.012_bb0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.drugpo.2014.09.012","article-title":"Social and recovery capital amongst homeless hostel residents who use drugs and alcohol","volume":"26","author":"Neale","year":"2015","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2019.03.012_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.drugalcdep.2016.06.006","article-title":"Development and validation of \u2018sure\u2019: A patient reported outcome measure (prom) for recovery from drug and alcohol dependence","volume":"165","author":"Neale","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2019.03.012_bb0100","doi-asserted-by":"crossref","first-page":"E317","DOI":"10.1503\/cmaj.110669","article-title":"Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment","volume":"184","author":"Nosyk","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.jsat.2019.03.012_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2017.02.021","article-title":"Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder","volume":"176","author":"Oviedo-Joekes","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2019.03.012_bb0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2019.03.012_bb0115","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes, E., Guh, D., Brissette, S., Marchand, K., MacDonald, S., Lock, K., \u2026 Schechter, M. T. (2016). Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry, 73(5), 1\u20139.","DOI":"10.1001\/jamapsychiatry.2016.0109"},{"key":"10.1016\/j.jsat.2019.03.012_bb0120","unstructured":"Oviedo-Joekes, E., Marchand, K., Guh, D., MacDonald, S., Lock, K., Brissette, S., \u2026 Schechter, M. T. (2015a). History of treatment access and drug use among participants in a trial testing injectable opioids under supervision for long-term heroin injectors. Journal of Addiction Medicine, 3(1), 1015."},{"key":"10.1016\/j.jsat.2019.03.012_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/1747-597X-10-3","article-title":"The SALOME study: Recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency","volume":"10","author":"Oviedo-Joekes","year":"2015","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2019.03.012_bb0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/16066359.2016.1263729","article-title":"Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder","volume":"25","author":"Oviedo-Joekes","year":"2017","journal-title":"Addiction Research and Theory"},{"issue":"5","key":"10.1016\/j.jsat.2019.03.012_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamapsychiatry.2016.0139","article-title":"Meeting the growing need for heroin addiction treatment","volume":"73","author":"Schottenfeld","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2019.03.012_bb0140","doi-asserted-by":"crossref","unstructured":"Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., \u2026 Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. doi:https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"10.1016\/j.jsat.2019.03.012_bb0145","series-title":"New heroin-assisted treatment: Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond: EMCDDA","author":"Strang","year":"2012"},{"issue":"9729","key":"10.1016\/j.jsat.2019.03.012_bb0150","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","article-title":"Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial","volume":"375","author":"Strang","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jsat.2019.03.012_bb0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1360-0443.2003.00354.x","article-title":"Does retention matter? Treatment duration and improvement in drug use","volume":"98","author":"Zhang","year":"2003","journal-title":"Addiction"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:07Z","timestamp":1760039347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218304409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":31,"alternative-id":["S0740547218304409"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.03.012","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}